3/14/2023 4:09:41 PM
Verastem Oncology Q4 Loss/share $0.08 Vs. Loss $0.09 Year Ago
10/20/2022 7:15:10 AM
Verastem Oncology Appoints Anil Kapur To Board
10/4/2022 7:12:44 AM
Verastem Oncology Announces Update On Raf And Mek Program
clinical Trials
8/8/2022 7:41:02 AM
Verastem Oncology Reports Q2 Nil Revenue
8/8/2022 7:28:51 AM
Verastem Oncology Q2 Net Loss/shr $0.12 Vs. Loss/shr $0.10 Last Year
7/7/2022 7:02:58 AM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/6/2022 7:15:23 AM
Verastem Oncology Provides Update On RAMP 201 Study Evaluating VS-6766 Defactinib In Low-Grade Serous Ovarian Cancer
3/28/2022 7:27:47 AM
Verastem Oncology Enters Credit Facility With Oxford Finance LLC For Up To $150 Mln
3/28/2022 7:17:10 AM
Verastem Oncology Q4 Net Loss $16.5 Mln Or $0.09/shr Vs Loss Of $19.9 Mln Or $0.12/shr Last Year
11/22/2021 7:41:07 AM
Mirati, Verastem Partner To Evaluate Adagrasib In Combination With VS-6766 In KRASG12C-Mutant Non-Small Cell Lung Cancer
9/22/2021 7:08:06 AM
Verastem Oncology Appoints Louis Denis As Chief Medical Officer
9/20/2021 7:11:30 AM
Verastem Oncology,Amgen Partner To Evaluate VS-6766 In With LUMAKRASTM In Patients With KRAS G12C-Mutant NSCLC
9/19/2021 12:05:06 PM
Verastem Oncology Presents Updated Phase 1/2 FRAME Data Of VS-6766 With Defactinib In Serous Ovarian Cancer At ESMO
7/6/2021 7:05:57 AM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/24/2021 7:11:15 AM
Verastem Oncology Appoints Paul Bunn And Lesley Solomon To Board
5/24/2021 7:09:16 AM
Verastem Gets Breakthrough Therapy Designation For VS-6766 With Defactinib In Recurrent Low-Grade Serous Ovarian Cancer
1/6/2021 9:15:20 AM
Verastem Appoints Frank Neumann As Chief Medical Officer
7/11/2014 12:39:29 PM
Deutsche Bank Reiterates Verastem, Inc. (VSTM) At Buy With $14 Price Target